Cowen & Co. Sticks to Its Buy Rating for Epizyme (EPZM)

By Austin Angelo

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Epizyme (NASDAQ: EPZM) today. The company’s shares opened today at $11.45.

According to, Nadeau is a 5-star analyst with an average return of 12.2% and a 56.4% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Alexion Pharmaceuticals, and Vertex Pharmaceuticals.

Epizyme has an analyst consensus of Strong Buy, with a price target consensus of $22.40, a 95.6% upside from current levels. In a report issued on September 21, Citigroup also maintained a Buy rating on the stock.


See today’s analyst top recommended stocks >>

Based on Epizyme’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $12 million and GAAP net loss of $29.13 million. In comparison, last year the company earned revenue of $10 million and had a GAAP net loss of $28.02 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Develops therapeutics for the treatment of patients with genetically defined cancers